A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤ 60 mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤ 200 mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
Introduction
Multiple sclerosis (MS) is a devastating disease of the central nervous system that causes loss of neurological function of motor and cognitive pathways. The disease is marked by progressive demyelination of white matter tissue leading to axonal loss and severe functional impairment. One of the most important issues facing researchers today is how to reverse the MS disease process and promote CNS repair in order to have a meaningful impact on the quality of life for affected MS subjects. Recent findings suggest that reducing inflammation in the brain can slow disease progression and promote natural repair processes. Additionally, new drugs are being sought to attract myelin producing cells into areas of damage and induce active production of myelin that wraps axons to restore neurological function.
We designed a novel therapeutic drug for MS called recombinant T cell receptor ligand (RTL) 1000 that was evaluated recently in a Phase 1 safety study. RTL1000 as well as other RTL constructs can inhibit the inflammatory activity of T cells that attack and destroy myelin and can reverse clinical paralysis in mice developing experimental autoimmune encephalomyelitis (EAE), an MS-like disease. To our surprise, we also discovered that successfully treated mice had evidence of remyelination and axonal regeneration, raising the possibility that RTLs could promote CNS repair. The potent therapeutic effects of RTLs in reversing clinical and histological signs of EAE and their possible remyelinating and neuroprotective effects on damaged CNS tissue provide a strong rationale for testing RTL therapy in subjects with multiple sclerosis.
Preclinical studies using RTLs in EAE

Rational design of recombinant TCR ligands (RTLs)
To develop a simple and effective agent that could bind selectively to the TCR, we designed molecules consisting of the α1 and β1 domains of MHC class II molecules genetically linked to autoantigenic peptides and expressed as a single polypeptide chain. Molecules with this design would be useful for studying binding specificity in vitro, for exploring primary TCR signaling events independent of co-stimulatory input associated with the MHC II α2 and β2 domains or with other molecules expressed by antigen presenting cells, and for treating CD4+ T cellmediated autoimmune disease in an MHC II/epitope-specific manner.
The single chain RTLs derived from the α1 and β1 domains of MHC class II molecules refold in a manner that allows binding of allelespecific epitopes that associate either as free peptides or as genetically engineered N-terminal extensions. The folded molecules can be recovered in high yield from inclusion bodies with a final yield of approximately 15-30 mg/l culture. Conformational integrity of the molecules was inferred from the presence of a disulfide bond between cysteines β15 and β79 and biological activity by direct antigenspecific binding to TCR on T cell hybridomas (Burrows et al., 1998) . Because of their biochemical stability, biological properties, and structural similarity with human class II homologues, RTLs represent a template for producing a novel class of unique therapeutic Journal of Neuroimmunology 231 (2011) 7-14 
